Ir para o conteúdo principal
Tradução em andamento — este conteúdo está sendo exibido em inglês enquanto a versão no seu idioma está sendo preparada.
Voltar para Discussões

Medicaid Prior Authorization and Discontinuation of Buprenorphine

Healthcare
United States
Iniciado June 30, 2026

This study assesses the duration of buprenorphine episodes paid by fee-for-service and managed care organization plans with and without prior authorization (PA) in Medicaid

Artigos de Fontes

Adicionar afirmação Análise 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
5 afirmações para votar • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 5/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Publicado por will • Jun 30, 2026
Prior authorization requirements can create unnecessary barriers, ultimately leading to increased healthcare costs and worsening public health outcomes.

Tradução pendente

Vote options for this statement: agree, disagree, or unsure
💬 Ver discussão
Be first to respond
Vote to see results
CLAIM Publicado por will • Jun 30, 2026
Prior authorization for buprenorphine in Medicaid can ensure that only patients who truly need it receive the medication, promoting responsible prescribing.

Tradução pendente

Vote options for this statement: agree, disagree, or unsure
💬 Ver discussão
Be first to respond
Vote to see results
CLAIM Publicado por will • Jun 30, 2026
Implementing prior authorization can help Medicaid control expenditures on buprenorphine, ensuring funds are used efficiently for other healthcare needs.

Tradução pendente

Vote options for this statement: agree, disagree, or unsure
💬 Ver discussão
Be first to respond
Vote to see results
CLAIM Publicado por will • Jun 30, 2026
While prior authorization may streamline costs, it risks delaying critical treatment for patients needing buprenorphine for recovery.

Tradução pendente

Vote options for this statement: agree, disagree, or unsure
💬 Ver discussão
Be first to respond
Vote to see results
CLAIM Publicado por will • Jun 30, 2026
The discontinuation of buprenorphine due to prior authorization is detrimental, as it limits access for individuals battling opioid addiction.

Tradução pendente

Vote options for this statement: agree, disagree, or unsure
💬 Ver discussão
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us